Literature DB >> 29971683

Budd-Chiari syndrome has different presentations and disease severity during adolescence.

Akash Shukla1, Pratin Bhatt2, Deepak Kumar Gupta2, Tejas Modi2, Jatin Patel2, Amit Gupte2, Megha Meshram2, Shobna Bhatia2.   

Abstract

There are limited data on clinical profile of adolescent patients with Budd-Chiari syndrome (BCS). We studied clinical, radiological, thrombophilia profile and treatment outcomes in adolescent patients with BCS.
METHODS: Forty-three consecutive patients of BCS with onset of symptoms during adolescence (10-19 years) were enrolled in the study. 129 randomly selected adult patients with BCS and 36 children with BCS formed the two control groups. The clinical history, physical examination, laboratory tests, thrombophilic disorders, radiological features and treatment outcomes of adolescents were compared to adults and children.
RESULTS: In adolescents, ascites (25/43 vs. 110/129, p = 0.0004) and thrombophilic disorders (16/43 vs. 93/129 p < 0.0001) were less frequent than adults. More adolescents (14/43) presented with hepatomegaly alone without ascites than adults (9/129, p < 0.001) or children (1/36, p = 0.005). Adolescents had lower Clichy scores [3.75 (1.2)] than adults [4.72 (1.3), p < 0.0001) or children [4.43 (1.7), p = 0.041]. JAK-2 V617F mutation was the most common thrombophilic disorder in adolescents (5/43) and more common than children (0/36, p = 0.043). Response to therapy was better in adolescents (74.4%) than children (52.8%, p = 0.038), but similar to adults (63.56%, p = 0.13).
CONCLUSION: During adolescence, patients with BCS present less commonly with ascites and may present with hepatomegaly alone. JAK-2 V617F mutation is the most common thrombophilic disorder during adolescence; though thrombophilic disorders are less common in adolescents than adults. Response to therapy is similar to adults, but better than children.

Entities:  

Keywords:  Anticoagulation therapy; Hepatic vein outflow tract obstruction; Pediatric liver disease; Portal hypertension; Trans-jugular intrahepatic porto-systemic shunt

Mesh:

Substances:

Year:  2018        PMID: 29971683     DOI: 10.1007/s12072-018-9880-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  24 in total

Review 1.  The role of sex steroids in controlling pubertal growth.

Authors:  R J Perry; C Farquharson; S F Ahmed
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-20       Impact factor: 3.478

2.  Clinicopathological forms and prognostic index in Budd-Chiari syndrome.

Authors:  Philippe Langlet; Sylvie Escolano; Dominique Valla; Delphine Coste-Zeitoun; Cecile Denie; Alain Mallet; Victor-Georges Levy; Dominique Franco; Jean-Pierre Vinel; Jacques Belghiti; Didier Lebrec; Jean-Marie Hay; Guy Zeitoun
Journal:  J Hepatol       Date:  2003-10       Impact factor: 25.083

3.  Diagnosis, management, and long-term issues in pediatric Budd-Chiari syndrome.

Authors:  Vikrant Sood; Rajeev Khanna; Dinesh Rawat; Seema Alam
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-09       Impact factor: 2.566

4.  Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.

Authors:  Jitka Veselovska; Dagmar Pospisilova; Sona Pekova; Monika Horvathova; Renata Solna; Jana Cmejlova; Radek Cmejla; Monika Belickova; Vladimir Mihal; Jan Stary; Vladimir Divoky
Journal:  Leuk Res       Date:  2007-08-23       Impact factor: 3.156

Review 5.  Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion.

Authors:  K Okuda; M Kage; S M Shrestha
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

Review 6.  Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.

Authors:  J B Dilawari; P Bambery; Y Chawla; U Kaur; S R Bhusnurmath; H S Malhotra; G K Sood; S K Mitra; S K Khanna; B S Walia
Journal:  Medicine (Baltimore)       Date:  1994-01       Impact factor: 1.889

7.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

Review 8.  Budd-Chiari syndrome in children: clinical features, percutaneous radiological intervention, and outcome.

Authors:  Rachana Kathuria; Anshu Srivastava; Surender K Yachha; Ujjal Poddar; Sanjay S Baijal
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-09       Impact factor: 2.566

9.  [Budd-Chiari syndrome in children and adolescents: therapeutic radiological intervention].

Authors:  Lei Wang; Mao-heng Zu; Yu-ming Gu; Hao Xu; Qing-qiao Zhang; Ning Wei; Wei Xu; Yan-feng Cui; Fei Teng; Qian-jin Hua
Journal:  Zhonghua Er Ke Za Zhi       Date:  2013-08

Review 10.  Budd-Chiari syndrome associated with antiphospholipid antibodies in a child: report of a case and review of the literature.

Authors:  L F Saca; I S Szer; E Henar; P Nanjundiah; Z H Haddad; F P Quismorio
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

View more
  5 in total

1.  Budd-Chiari syndrome: a focussed and collaborative approach.

Authors:  Amar Mukund; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-10-08       Impact factor: 6.047

2.  Presence of Ascites at Presentation is Associated With Absence of Long-Term Response Amongst Patients With Budd-Chiari Syndrome When Treated With Medical Therapy Alone: A Single Centre Real-Life Experience.

Authors:  Dhiraj Agrawal; Deepak Gupta; Rohit Nathani; Prashant Dhore; Megha Meshram; Shobna J Bhatia; Akash Shukla
Journal:  J Clin Exp Hepatol       Date:  2021-11-03

3.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

Review 4.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

Review 5.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.